Status:
COMPLETED
A Study to Assess Drug Levels, Tolerability and Absolute Biological Availability of Single-dose of BMS-986446 in Healthy Participants
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Healthy Volunteer
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to assess drug levels, tolerability and absolute biological availability of single subcutaneous dose of BMS-986446 in healthy participants
Eligibility Criteria
Inclusion
- Participants must have a Body Mass Index (BMI) of 18.0 to 30.0 kg/m2.
- Participants must be healthy as determined by medical history, physical examination, neurological examination, vital signs, 12-lead ECG, C-SSRS, and clinical laboratory evaluations.
Exclusion
- Participants must not have clinically significant gastrointestinal, renal, hepatic, broncho-pulmonary, neurological, psychiatric, cardiovascular, endocrinological, immune-mediated disorder, hematological, ongoing allergic disorder requiring treatment, metabolic disorder, cancer, or cirrhosis.
- Participants must not have prior exposure to BMS-986446 (PRX005).
- Other protocol-defined Inclusion/Exclusion criteria apply.
Key Trial Info
Start Date :
May 5 2025
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 11 2025
Estimated Enrollment :
46 Patients enrolled
Trial Details
Trial ID
NCT06955741
Start Date
May 5 2025
End Date
September 11 2025
Last Update
October 1 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution - 0001
Anaheim, California, United States, 92801
2
Local Institution - 10000
Anaheim, California, United States, 92801